The company’s research highlights at ESMO 2026 center on durable survival outcomes for advanced bladder cancer patients treated with the combination of PADCEV and pembrolizumab. Beyond these established regimens, the clinical program emphasizes the role of CLDN18.2 biomarkers in shaping gastric and gastroesophageal junction cancer treatment, alongside real-world evidence for XTANDI in prostate cancer management.

Moitreyee Chatterjee-Kishore, Executive Vice President of Oncology Development, noted that the data reflect a broader shift toward integrating disease biology into clinical decision-making. The company is positioning these findings to address significant gaps in care for patients who have exhausted traditional options. The presentations also feature progress in the development pipeline, specifically Phase 3 trials of setidegrasib for pancreatic and lung cancers, as well as early-stage investigations into targeted therapies for KRAS-mutated tumors.